PNPase Inhibitors for Bladder Dysfunction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bladder and urethra dysfunction in the elderly population are inadequate, with existing options failing to effectively address age-related changes such as decreased bladder contractility, increased oxidative stress, and mitochondrial dysfunction, leading to urinary incontinence and other symptoms.
Innovation Solution
Administration of PNPase inhibitors or PNPase purine nucleoside substrates, such as 8-aminoguanine, to improve bladder and urethral function by increasing smooth muscle contractility, reducing oxidative stress, and restoring mitochondrial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for bladder and urethra dysfunction in the elderly, then treatment is provided, but the treatments fail to effectively address age-related changes such as decreased bladder contractility, increased oxidative stress, and mitochondrial dysfunction
Solution Approach 1:
The patent applies parameter changes by targeting specific biochemical parameters in aged bladder and urethral tissue. PNPase inhibitors and purine nucleoside substrates modify the metabolic state of smooth muscle cells, reversing age-related changes in contractility, oxidative stress levels, and mitochondrial function. This transforms the treatment approach from generic symptom management to targeted biochemical parameter modification, effectively addressing multiple age-related pathological changes simultaneously.
2Force
If PNPase inhibitors or PNPase purine nucleoside substrates are administered to improve bladder contractility, then smooth muscle contractility increases, but the mechanism involves complex interactions with oxidative stress and mitochondrial function
Solution Approach 1:
The patent employs PNPase inhibitors and purine nucleoside substrates as intermediary compounds that mediate the restoration of smooth muscle function. These agents act as biochemical intermediaries that restore purine nucleoside metabolism, which in turn restores energy production and contractile function. The intermediary compounds bridge the gap between age-related metabolic dysfunction and the desired physiological outcome of improved contractility, simplifying the treatment approach while addressing complex underlying mechanisms.
3Reliability
If PNPase inhibitors or PNPase purine nucleoside substrates are administered to reduce oxidative stress, then tissue morphology and mitochondrial health are restored, but the treatment must address multiple pathological factors simultaneously
Solution Approach 1:
The patent applies universality by demonstrating that PNPase inhibitors and purine nucleoside substrates perform multiple therapeutic functions simultaneously. These single agents address oxidative stress, restore mitochondrial function, improve smooth muscle contractility, and restore tissue morphology across both bladder and urethral tissues. This multi-functional approach eliminates the need for multiple separate treatments targeting different age-related pathological factors, simplifying the therapeutic regimen while comprehensively addressing the complex syndrome of lower urinary tract dysfunction in the elderly.
Data Source
AI summary
Methods of treating bladder or urethra dysfunction or disease in a subject and methods of increasing bladder smooth muscle contractility or increasing bladder wall volume in a subject are disclosed. In some examples, a purine nucleoside phosphorylase (PNPase) inhibitor or purine nucleoside substrate is administered, such as 8-aminoguanine or forodesine.